Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BG Medicine to collaborate with Applied Biosystems
Under the terms of the agreement, BG Medicine will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore
Under the terms of the agreement, BG Medicine will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore
Aradigm previously received orphan drug designation for the same formulation of ciprofloxacin for the management of cystic fibrosis in April 2006. Aradigm's liposomal ciprofloxacin is an aerosolized formulation
Neupro has been available in the European market since March 2006 for the treatment of early stage idiopathic Parkinson's disease as a monotherapy. The drug has already been
Bicifadine is a serotonin and norepinephrine reuptake inhibitor (SNRI). Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is
Pharming believes that although the number of transplantations is currently relatively small, DGF is an important medical need providing a significant market opportunity. Transplantation procedures are costly and
MER 103 is an enteric-coated tablet of Fosamax and GIPET, Merrion’s platform technology which increases drug absorption. The study confirmed several important improvements for patient convenience and compliance
The agreement concerns Crucell’s STAR technology which is useful for increasing production of recombinant antibodies and therapeutic proteins on mammalian cell lines. STAR technology supports high yield antibody
If successful, oral cladribine will be the first oral therapy for multiple sclerosis with the convenience of short courses of therapy with intermittent administration. The study will provide
Prolysis is aiming to develop new antibacterial compounds to tackle life-threatening, drug-resistant infections caused by staphylococci, including MRSA. MRSA is fast becoming untreatable with the currently available antibiotics.
In Europe, orphan drug designation provides market exclusivity for up to 10 years to companies that develop drugs for underserved patient populations. Prochymal has already been granted both